Key result
Epicardial adipose tissue-derived kynurenic acid increases AF susceptibility by impairing atrial lymphangiogenesis via GPR35.
Why the study?
Atrial fibrillation is a prevalent cardiac arrhythmia whose pathogenic mechanisms remain incompletely understood.
Does promoting lymphangiogenesis via VEGFC or LY3437943 reduce atrial fibrillation inducibility in preclinical models?
Does promoting lymphangiogenesis via VEGFC or LY3437943 reduce atrial fibrillation inducibility in preclinical models?
This study identifies lymphatic dysfunction driven by epicardial fat-derived kynurenic acid as a novel pathogenic mechanism in atrial fibrillation, suggesting lymphangiogenesis as a potential therapeutic target.
May link reduced atrial lymphatics to AF persistence; leaves open whether lymphangiogenic therapies could modify outcomes.
Atrial fibrillation represents a prevalent cardiac arrhythmia whose pathogenic mechanisms remain incompletely understood. Here, we identify impaired atrial lymphangiogenesis as a critical determinant in atrial fibrillation pathogenesis. Analysis of human left atrial appendage specimens reveals decreased lymphatic vessel density in atrial fibrillation patients compared to those in sinus rhythm. Mechanistically, we demonstrate that epicardial adipose tissues from atrial fibrillation patients secrete kynurenic acid, which acts via GPR35 to disrupt lymphatic endothelial cell metabolism and mitochondrial homeostasis, ultimately promoting endothelial-to-mesenchymal transition. Using an organotypic culture system, we show that epicardial adipose tissue -derived factors directly impair lymphatic vessel formation. In vivo studies utilizing angiotensin II-induced and high-fat diet male mouse models confirm the critical role of lymphatic dysfunction in atrial fibrillation susceptibility. Therapeutic interventions promoting lymphangiogenesis, either through VEGFC administration or weight loss intervention by LY3437943 (the novel triple GIP, GLP-1, and glucagon receptor agonist), significantly attenuate atrial fibrillation inducibility. These findings establish lymphatic dysfunction as a novel pathogenic mechanism in atrial fibrillation and highlight lymphatic vessel formation as a promising therapeutic target.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2026) studied Atrial fibrillation (n=42). Kynurenic acid vs. Vehicle / No AFib controls was evaluated on Lymphatic vessel density and lymphangiogenesis-related gene expression. Epicardial adipose tissue-derived kynurenic acid disrupts lymphatic endothelial cell metabolism via GPR35, leading to impaired atrial lymphangiogenesis and increased susceptibility to atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: